This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
A large randomised double-blinded trial reporting a considerable benefit ( 0.79 HR with very small p and supporting confidence intervals) of the Boehringer SGLPT-2 inhibitor regardless of presence of formal diagnosis of diabetes. If corroborated by further research and thence included on guidelines , the findings may alter the standard of pharmacological care of our surgical patients, namely coronopaths and vasculopaths .